Literature DB >> 33472952

Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer.

Emelie Foord1, Lucas C M Arruda2, Ahmed Gaballa2,3, Charlotte Klynning4, Michael Uhlin2,5,6.   

Abstract

The role of γδ T cells in antitumor immunity has been under investigation for the past two decades, but little is known about their contribution to clinical outcomes in patients. Here, we set out to define the clonotypic, phenotypic, and functional features of γδ T cells in peripheral blood, ascites, and metastatic tumor tissue from patients with advanced epithelial ovarian cancer. T cell receptor (TCR) sequencing of the γ chain revealed that tumor-infiltrating γδ T cells have a unique and skewed repertoire with high TCR diversity and low clonality. In contrast, ascites-derived γδ T cells presented a lower TCR diversity and higher clonality, suggesting a TCR-dependent clonal focusing at this site. Further investigation showed that tumor samples had abundant γδ T cells with a tissue-resident, activation-associated phenotype, less usage of Vγ9 and an impaired response to adaptive-associated stimuli, implying an innate-like activation pathway, rather than an adaptive TCR-engaging pathway, at these tumor sites. Furthermore, high γδ T cell cytokine responsiveness upon stimulation was associated with a favorable outcome for patients in terms of both overall survival and reduced residual tumor burden after primary surgery. Last, the functionality of γδ T cells and patient survival were negatively affected by the proportions of CD39-expressing T cells, highlighting the potential of CD39 as a target to improve γδ T cell responses and unleash their antitumor capabilities.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33472952     DOI: 10.1126/scitranslmed.abb0192

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  11 in total

1.  Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes.

Authors:  Xiaofeng Mu; Zheng Xiang; Yan Xu; Jing He; Jianwen Lu; Yuyuan Chen; Xiwei Wang; Chloe Ran Tu; Yanmei Zhang; Wenyue Zhang; Zhinan Yin; Wing-Hang Leung; Yu-Lung Lau; Yinping Liu; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2022-07-11       Impact factor: 22.096

2.  Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

Authors:  Frank G Lawton; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-03-24

3.  A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.

Authors:  Yin Wu; Dhruva Biswas; Ieva Usaite; Mihaela Angelova; Stefan Boeing; Takahiro Karasaki; Selvaraju Veeriah; Justyna Czyzewska-Khan; Cienne Morton; Magdalene Joseph; Sonya Hessey; James Reading; Andrew Georgiou; Maise Al-Bakir; Nicholas McGranahan; Mariam Jamal-Hanjani; Allan Hackshaw; Sergio A Quezada; Adrian C Hayday; Charles Swanton
Journal:  Nat Cancer       Date:  2022-05-30

4.  Single-Cell RNAseq Profiling of Human γδ T Lymphocytes in Virus-Related Cancers and COVID-19 Disease.

Authors:  Juan Pablo Cerapio; Marion Perrier; Fréderic Pont; Marie Tosolini; Camille Laurent; Stéphane Bertani; Jean-Jacques Fournie
Journal:  Viruses       Date:  2021-11-03       Impact factor: 5.048

5.  γδ T cell costimulatory ligands in antitumor immunity.

Authors:  Joseph M McGraw; Deborah A Witherden
Journal:  Explor Immunol       Date:  2022-02-24

Review 6.  Gamma delta T-cell reconstitution after allogeneic HCT: A platform for cell therapy.

Authors:  Ahmed Gaballa; Lucas C M Arruda; Michael Uhlin
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

7.  Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell.

Authors:  Rui Yang; Qing He; Hui Zhou; Cheng Gong; Xing Wang; Xingpan Song; Fang Luo; Yang Lei; Qian Ni; Zili Wang; Shasha Xu; Yan Xue; Man Zhang; Haimei Wen; Lijuan Fang; Liang Zeng; Yongxiang Yan; Jian Shi; Jing Zhang; Jizu Yi; Pengfei Zhou
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

8.  Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers.

Authors:  Juan-Pablo Cerapio; Marion Perrier; Camille-Charlotte Balança; Pauline Gravelle; Fréderic Pont; Christel Devaud; Don-Marc Franchini; Virginie Féliu; Marie Tosolini; Carine Valle; Fréderic Lopez; Anne Quillet-Mary; Loic Ysebaert; Alejandra Martinez; Jean Pierre Delord; Maha Ayyoub; Camille Laurent; Jean-Jacques Fournie
Journal:  Oncoimmunology       Date:  2021-09-18       Impact factor: 8.110

9.  Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.

Authors:  Pauline Weimer; Jasmin Wellbrock; Tabea Sturmheit; Leticia Oliveira-Ferrer; Yi Ding; Stephan Menzel; Marius Witt; Louisa Hell; Barbara Schmalfeldt; Carsten Bokemeyer; Walter Fiedler; Franziska Brauneck
Journal:  Cells       Date:  2022-03-11       Impact factor: 6.600

Review 10.  The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.

Authors:  Susann Schönefeldt; Tamara Wais; Marco Herling; Satu Mustjoki; Vasileios Bekiaris; Richard Moriggl; Heidi A Neubauer
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.